Boron neutron capture therapy combined with X-ray fractionation and temozolomide for newly-diagnosed malignant glioma

Boron neutron capture therapy combined with X-ray fractionation and temozolomide for newly-diagnosed malignant glioma - BNCT combined with X-ray fractionation and TMZ

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003984

Enrollment

Registered

2010-08-03

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant glioma

Interventions

Boron compound: Boronophenylalanine(BPA) 250mg/kg, i.v. Neuroron irradiation: Maximum point dose for the brain and skin should be less than 13Gy-Eq X-ray fractionation 40Gy/20fr temozolomide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)age: 15or older, 80> 2)Karnofski score: 50%or more 3)supratentorial unilateral tumor 4)no deeper than 7cm from the brain surface 5)written informed consent 6)co-operation for follow-up

Exclusion criteria

Exclusion criteria: 1)Dissemination 2)blood analyses AST,ALT > 100IU/ml , Bilirubin > 2.0mg% BUN > 30mg/dl , Cr > 1.8mg% WBC < 2500/mm3 , Plt < 75000/mm3 , Hb < 8g/dl 3)prior radiation 4)double cancer 5)phenylketonuria 6)considerable complications 7)other important condition which is inappropriater for the trial

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Countries

Japan

Contacts

Public ContactTetsuya Yamamoto

University of Tsukuba Department of Neurosurgery

029-853-3220

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026